183 related articles for article (PubMed ID: 37844346)
1. Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer.
Niu ZX; Wang YT; Lu N; Sun JF; Nie P; Herdewijn P
Eur J Med Chem; 2023 Dec; 261():115868. PubMed ID: 37844346
[TBL] [Abstract][Full Text] [Related]
2. Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents.
Belani CP; Ramanathan RK
Chest; 1998 Jan; 113(1 Suppl):53S-60S. PubMed ID: 9438691
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
4. Advances in systemic therapy for non-small cell lung cancer.
Miller M; Hanna N
BMJ; 2021 Nov; 375():n2363. PubMed ID: 34753715
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
Devarakonda S; Morgensztern D; Govindan R
Clin Lung Cancer; 2013 Sep; 14(5):467-72. PubMed ID: 23684057
[TBL] [Abstract][Full Text] [Related]
6. Non-surgical therapy for patients with advanced non-small cell lung cancer.
Liao M
Respirology; 1998 Sep; 3(3):151-7. PubMed ID: 9767613
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
Castillo DR; Jeon WJ; Park D; Pham B; Yang C; Joung B; Moon JH; Lee J; Chong EG; Park K; Reeves ME; Duerksen-Hughes P; Mirshahidi HR; Mirshahidi S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511306
[TBL] [Abstract][Full Text] [Related]
9. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
10. Radiation and third-generation chemotherapy.
Chen Y; Okunieff P
Hematol Oncol Clin North Am; 2004 Feb; 18(1):55-80. PubMed ID: 15005281
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X; Martín M; Remon J; Higuera O; Calvo V; Jarabo JR; Conde E; Luna J; Provencio M; De Castro J; López-Ríos F; Hernando-Trancho F; Couñago F
Future Oncol; 2021 Oct; 17(30):4011-4025. PubMed ID: 34337973
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by radical local therapy for locally advanced non-small cell lung cancer.
Wendland MM; Sause WT
Semin Surg Oncol; 2003; 21(2):111-21. PubMed ID: 14508861
[TBL] [Abstract][Full Text] [Related]
13. Complex and controversial issues in locally advanced non-small cell lung carcinoma.
Machtay M; Jeremic B
Semin Surg Oncol; 2003; 21(2):128-37. PubMed ID: 14508863
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lung cancer.
Gadgeel SM; Ramalingam SS; Kalemkerian GP
Radiol Clin North Am; 2012 Sep; 50(5):961-74. PubMed ID: 22974781
[TBL] [Abstract][Full Text] [Related]
17. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced non-small cell lung cancer: the past, present, and future.
Govindan R; Bogart J; Vokes EE
J Thorac Oncol; 2008 Aug; 3(8):917-28. PubMed ID: 18670313
[TBL] [Abstract][Full Text] [Related]
20. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
